Guardant Health, Which Tests for Cancer Through Blood Samples, Raises $100M In Series D Funding

Guardant Health, a three-year-old start-up has raised nearly $100 million in Series D funding. The financing was led by OrbiMed Advisors. The California based company developed a non-invasive genomic sequencing test for cancer which requires just two vials of blood.  Guardant has now raised almost $200 million altogether. Read More>>

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s